Clinical Trials Logo

Obsessive-Compulsive Disorder clinical trials

View clinical trials related to Obsessive-Compulsive Disorder.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT04880278 Withdrawn - Clinical trials for Obsessive-Compulsive Disorder

Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder

Start date: March 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this research study is to test how a medication called nabilone (Cesamet) affects neurocognitive processes involved in obsessive-compulsive disorder (OCD), including threat response, processing of fear signals, and habitual behavior. OCD is a disabling illness that affects around 2% of the population and involves recurrent intrusive thoughts (obsessions) and repetitive behaviors (compulsions) that lead to distress and/or impaired functioning. Nabilone is a synthetic form of delta-9-tetrahydrocannabinol (THC, the primary psychoactive component of the cannabis plant). It acts on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD symptoms. Nabilone is approved by the FDA for the treatment of chemotherapy-induced nausea and vomiting. It is not FDA-approved for treating OCD. In this study, 60 adults with OCD will receive a single dose of either nabilone or placebo. Participants will then complete a series of assessments including neuroimaging, psychophysiology (e.g., skin conductance recording), computerized behavioral tasks, and self-report measures. The information gained from this study could contribute to the development of new treatments for people with OCD and related disorders.

NCT ID: NCT04436952 Withdrawn - Clinical trials for Obsessive-Compulsive Disorder

Is There a New Gold Standard for the Treatment of Obsessive-Compulsive Disorder?

Start date: July 2020
Phase: N/A
Study type: Interventional

Obsessive Compulsive Disorder is a highly debilitating condition with a lifetime prevalence of 2%-3%, and a notable percentage of patients (40-60%) have a partial or no response to medications. The present gold standard for the treatment of OCD is medications (Selective serotonin reuptake inhibitors (SSRIs) / Clomipramine) + Exposure and Response Prevention (ERP). There is a significant need for alternative novel methods of treatment. One of the novel methods of treating OCD is using magnetic stimulation which has already been successfully used in the treatment of depression. Treating OCD is difficult with regular superficial repetitive Transcranial Magnetic Stimulation (rTMS) hence the need for coils that targets deeper structures. Thus, we are comparing the efficacy of the two different coils from two different manufacturers plus using ERP in combination with the different coils. 1. Deep Transcranial Magnetic Stimulation (DTMS) using BrainsWay H7 coil targets deeper structures such as medial prefrontal cortex. The H7 coil has already shown clear evidence in treating patients with OCD and has been approved by the FDA for clinical use. 2. Repetitive Transcranial Magnetic Stimulation (rTMS) using MagVenture Cool D-B coil could also target the medial prefrontal cortex. Hence it might also be equally effective as the BrainsWay H7 coil in treating patients with OCD.

NCT ID: NCT04283812 Withdrawn - Parkinson Disease Clinical Trials

New Stereotactic Frame System for Neurosurgery

Start date: January 2023
Phase: N/A
Study type: Interventional

This study is designed to demonstrate an in-house developed re-attachable stereotactic system that can markedly reduce the overall deep brain stimulation (DBS) procedure time to greatly facilitate subject access to neurosurgical restorative therapies. Subjects will consist exclusively of individuals who have been approved to undergo deep brain stimulation surgery for the treatment of a neurological disorder at Mayo Clinic - Rochester MN. This study is a quantitative comparative, between-subject study enrolling approximately 10 subjects.

NCT ID: NCT04215549 Withdrawn - Clinical trials for Obsessive-Compulsive Disorder

The Cost of Obsessive-compulsive Disorder (OCD) in China

OCD
Start date: January 2, 2020
Phase:
Study type: Observational

The purpose of this study is to estimate the cost of obsessive-compulsive disorder in China based on the prevalence rate from a social perspective.

NCT ID: NCT03926546 Withdrawn - OCD Clinical Trials

Individual Versus Group Exposure With Response Prevention (ERP) for the Treatment of Obsessive Compulsive Disorder (OCD)

Start date: May 2020
Phase: N/A
Study type: Interventional

The primary objective is to examine the efficacy of implementing evidence based Exposure and Response Prevention (ERP) within group therapy versus individual therapy by monitoring reduction of Obsessive-Compulsive Disorder (OCD) symptomology.

NCT ID: NCT03767491 Withdrawn - Clinical trials for Obsessive-Compulsive Disorder

Waitlist-Control Trial of Smartphone CBT for Obsessive-Compulsive Disorder (OCD)

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

The investigators are testing the efficacy of Smartphone-delivered cognitive behavioral therapy (CBT) treatment for obsessive compulsive disorder (OCD). The investigators hypothesize that participants receiving app-CBT will have greater improvement in Y-BOCS scores than those in the waitlist condition at treatment endpoint (week 12).

NCT ID: NCT03244852 Withdrawn - Clinical trials for Obsessive-Compulsive Disorder

Patient-specific, Effective, and Rational Functional Connectivity Targeting for DBS in OCD

PERFECT DBS
Start date: September 15, 2017
Phase:
Study type: Observational

The study aims to improve patient-specific anatomical targeting of the Deep Brain Stimulation for the treatment of intractable OCD.

NCT ID: NCT02955654 Withdrawn - Clinical trials for Obsessive-Compulsive Disorder

Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether acceptance and commitment therapy is effective in the treatment of SSRIs-resistant obsessive- compulsive disorder.

NCT ID: NCT02790710 Withdrawn - Clinical trials for Obsessive-compulsive Disorder

Brief Intervention for OCD Fears

Start date: June 2016
Phase: Phase 4
Study type: Interventional

The study will test the efficacy of propranolol or placebo, administered after reactivation of a previously acquired obsessive-compulsive disorder (OCD) fear, in reducing fear and avoidance in OCD.

NCT ID: NCT02450695 Withdrawn - Clinical trials for Obsessive-Compulsive Disorder

rTMS in Treatment Refractory Obsessive-Compulsive Disorder

Start date: July 2016
Phase: N/A
Study type: Interventional

This study will evaluate the effectiveness of rTMS as a potential treatment for refractory OCD in a randomized, crossover design.